NCNA

Peers: PCSA MBRX PPCB ACTU BYSI SLXN ATNM CRDF KZIA BDRX

Index	-
Market Cap	4.39M
Enterprise Value	-20.61M
Income	-13.03M
Sales	0.00M
Book/sh	0.04
Cash/sh	6.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Sep 28, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	27.20
P/C	0.17
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.73
Current Ratio	4.73
Debt/Eq	0.03
LT Debt/Eq	0.03
Option/Short	No / Yes

EPS (ttm)	-3.22
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	83.42% 68.08%
Sales past 3/5Y	- -
EPS Y/Y TTM	99.50%
Sales Y/Y TTM	-
EPS Q/Q	96.76%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	- -

Insider Own	6.99%
Insider Trans	0.00%
Inst Own	2.57%
Inst Trans	1.28%
ROA	-46.15%
ROE	-70.39%
ROIC	-46.96%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.08%
SMA50	-16.90%
SMA200	-41.38%
Trades

Shs Outstand	4.31M
Shs Float	4.01M
Short Float	3.62%
Short Ratio	1.22
Short Interest	0.15M
52W High	4.55 -77.59%
52W Low	0.95 7.51%
Volatility	6.72% 7.43%
ATR (14)	0.08
RSI (14)	41.55
Beta	2.40
Rel Volume	0.27
Avg Volume	119.27K
Volume	29,514

Perf Week	-1.96%
Perf Month	-6.46%
Perf Quarter	-26.65%
Perf Half Y	-53.86%
Perf YTD	-71.68%
Perf Year	-74.57%
Perf 3Y	-99.96%
Perf 5Y	-99.99%
Perf 10Y	-
Recom	3.00
Target Price	4750.48
Prev Close	1.01
Price	1.02
Change %	0.95%

Consensus

Hold

Avg. Price Target

$4,750.48

Implied Upside

+465,816.0%

Analysts8incl. previous ratings

Rating Distribution6 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 30, 2024	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Mar 03, 2022	Downgrade	CCowen	Outperform → Market Perform
Oct 22, 2020	Initiated	TTruist	Buy	$22	+2,057.7%
Jul 24, 2020	Initiated	OOppenheimer	Outperform
Aug 19, 2019	Initiated	HH.C. Wainwright	Buy	$20	+1,861.6%
Oct 19, 2018	Initiated	PPiper Jaffray	Overweight
Oct 23, 2017	Initiated	WWilliam Blair	Outperform
Oct 23, 2017	Initiated	JJefferies	Buy	$25	+2,351.9%
Oct 23, 2017	Initiated	CCitigroup	Buy	$23	+2,155.8%

Sep-30-26 08:00AM	NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe (GlobeNewswire) +11.57%
Aug-13-26 04:01PM	NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +7.43%
Jun-01-26 08:00AM	NuCana Appoints Ian Webster as Chief Financial Officer (GlobeNewswire) -6.87%
May-14-26 04:01PM	NuCana Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +5.88% +10.10%
Mar-19-26 04:01PM	NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update (GlobeNewswire)
08:00AM	Loading…
Jan-06-26 08:00AM	NuCana Appoints Theresa Bruce as Chief Operating Officer (GlobeNewswire)
Dec-10-25 08:00AM	NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma (GlobeNewswire)
Nov-13-25 04:01PM	NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -7.92%
Nov-05-25 08:00AM	NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China (GlobeNewswire)
Oct-18-25 08:00AM	NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025 (GlobeNewswire)
Oct-14-25 08:00AM	NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy (GlobeNewswire)
Sep-05-25 08:00AM	NuCana Compliant with All Nasdaq Continued Listing Criteria (GlobeNewswire)
Sep-03-25 08:00AM	NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025 (GlobeNewswire)
Aug-20-25 04:05PM	NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -12.64% +6.43%
Aug-01-25 04:05PM	NuCana Announces ADS Ratio Change (GlobeNewswire) -8.86% +16.88%
08:05AM	Loading…
Jul-21-25 08:05AM	NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution (GlobeNewswire) +6.92%
Jul-11-25 10:30AM	NuCana Announces Plan to Implement ADS Ratio Change (GlobeNewswire) -15.91%
Jun-02-25 04:01PM	NuCana Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +7.65% +57.37%
May-06-25 08:30AM	NuCana Prices $7 Million Registered Direct Offering (GlobeNewswire) -63.27%
Apr-25-25 07:06AM	Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season? (Zacks) -15.37%
Apr-09-25 10:58AM	RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks (Zacks)
Mar-20-25 04:01PM	NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-25-24 07:00AM	NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:00AM	NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel (GlobeNewswire)
Oct-04-24 01:03PM	Baillie Gifford's Strategic Acquisition of NuCana PLC Shares (GuruFocus.com)
Sep-25-24 04:01PM	NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States (GlobeNewswire) -8.41% -9.84%
Sep-16-24 09:24AM	NuCana's Encouraging Data From Resistant Melanoma Treatment Provides Some Relief After Disappointing Colorectal Cancer Data, Stock Surges (Benzinga) +150.79%
Sep-14-24 03:01AM	NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 (GlobeNewswire)
Aug-30-24 08:47AM	NuCana Stock Plunges On Colorectal Combo Therapy Trial Setback, Ends Mid-Stage Study After Disappointing Data (Benzinga) -52.65%
06:52AM	NuCana discontinues Phase II NuTide:323 colorectal cancer study (Clinical Trials Arena)
04:01PM	Loading…
Aug-29-24 04:01PM	NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study (GlobeNewswire)
Aug-15-24 04:01PM	NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.11% +6.38%
May-30-24 08:36AM	NuCana to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-24 08:00AM	NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-16-24 09:53PM	NCNA Stock Earnings: NuCana Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	NuCana Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 04:01PM	NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Apr-16-24 08:00AM	NuCana Announces Completion of ADS Ratio Change (GlobeNewswire) -12.36%
Apr-09-24 04:30PM	NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study (GlobeNewswire)
Mar-27-24 04:30PM	NuCana Announces Plan to Implement ADS Ratio Change (GlobeNewswire) -15.21%
Mar-20-24 09:53PM	NCNA Stock Earnings: NuCana Misses EPS for Q4 2023 (InvestorPlace) -12.92%
04:01PM	NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-13-24 07:52AM	Why Is NuCana (NCNA) Stock Up 102% Today? (InvestorPlace) +9.21%
Feb-27-24 08:00AM	NuCana to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-06-24 08:00AM	NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-16-23 04:01PM	NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-23 04:01PM	NuCana Announces Listing Transfer to Nasdaq Capital Market (GlobeNewswire)
Nov-08-23 04:01PM	NuCana to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -6.99%
Nov-01-23 04:01PM	NuCana to Participate in the Truist Securities 2023 BioPharma Symposium (GlobeNewswire)
Oct-16-23 07:00AM	NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (GlobeNewswire) -12.24%
Oct-13-23 12:30PM	NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (GlobeNewswire) -16.26%
Oct-10-23 08:46AM	Why Is NuCana (NCNA) Stock Down Today? (InvestorPlace)
Sep-28-23 09:55AM	Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now (Zacks)
Sep-18-23 08:00AM	NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (GlobeNewswire)
Aug-16-23 04:01PM	NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.25% +9.86%
Jun-01-23 08:00AM	NuCana to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-17-23 04:01PM	NuCana Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-12-23 04:01PM	NuCana Announces Receipt of Nasdaq Notice (GlobeNewswire)
Apr-14-23 08:00AM	NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action (GlobeNewswire)
Apr-04-23 04:01PM	NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update (GlobeNewswire) -8.32%
Mar-29-23 11:46AM	15 Top Performing European Stocks So Far in 2023 (Insider Monkey)
Mar-24-23 04:30PM	Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCanas 190 Patent is Not Valid (GlobeNewswire) -13.29% -35.23%
10:35AM	We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate (Simply Wall St.)
Feb-28-23 08:00AM	NuCana to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +11.54%
Jan-23-23 08:00AM	NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jan-06-23 04:01PM	NuCana Announces Receipt of NASDAQ Notice (GlobeNewswire) +12.84%
Jan-03-23 08:00AM	NuCana to Host Investor Meetings During the J.P. Morgan Healthcare Conference (GlobeNewswire) +15.15%
Nov-21-22 12:00PM	NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Nov-16-22 04:01PM	NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -6.60%
Nov-08-22 08:00AM	NuCana to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-26-22 07:00AM	NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022 (GlobeNewswire)
Oct-15-22 10:06AM	Is NuCana (NASDAQ:NCNA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-05-22 09:35AM	Here's Why NuCana PLC Sponsored ADR (NCNA) is Poised for a Turnaround After Losing 26.5% in 4 Weeks (Zacks)
Sep-28-22 12:00PM	NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:35AM	Down 34.6% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) (Zacks)
Sep-12-22 10:45AM	NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 (GlobeNewswire)
08:00AM	NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022 (GlobeNewswire)
Sep-06-22 08:00AM	NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022 (GlobeNewswire)
Aug-31-22 08:00AM	NuCana to Participate in Citi's 17th Annual BioPharma Conference (GlobeNewswire)
Aug-17-22 04:01PM	NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jul-27-22 08:00AM	NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-26-22 09:13AM	Here's What NuCana plc's (NASDAQ:NCNA) Shareholder Ownership Structure Looks Like (Simply Wall St.) -12.36%
Jul-11-22 01:36PM	Why NuCana Shares Are Rising Today? (Benzinga) +11.54%
08:00AM	German Court Rules that Gileads Sofosbuvir Infringes NuCanas 190 Patent (GlobeNewswire)
Jun-10-22 07:00AM	NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress (GlobeNewswire)
Jun-03-22 04:01PM	NuCana Announces Receipt of NASDAQ Notice (GlobeNewswire)
Jun-02-22 04:01PM	NuCana Reports First Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Jun-01-22 04:01PM	NuCana to Participate in the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-06-22 07:59AM	We Think NuCana (NASDAQ:NCNA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Apr-27-22 04:01PM	NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-15-22 11:09AM	BioNTech (BNTX) to Report Q4 Earnings: What's in the Cards? (Zacks) +11.04%
Mar-08-22 04:35PM	NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire) -8.66% +13.94%
Mar-04-22 10:00AM	Down 57.3% in 4 Weeks, Here's Why You Should You Buy the Dip in NuCana PLC Sponsored ADR (NCNA) (Zacks) -20.55%
Mar-03-22 06:13AM	Why Did NuCana Stop Phase 3 Biliary Tract Cancer Trial? (Benzinga) -59.18%
Mar-02-22 04:01PM	NuCana Announces Update for Phase 3 Biliary Tract Cancer Study (GlobeNewswire)
Feb-28-22 04:01PM	NuCana to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +7.04%
Feb-22-22 04:01PM	NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study (GlobeNewswire)
Feb-01-22 10:53AM	What You Need To Know About NuCana plc's (NASDAQ:NCNA) Investor Composition (Simply Wall St.) +5.26%
Jan-24-22 09:40AM	Is NuCana PLC Sponsored ADR (NCNA) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) -5.33%

Show Previous News

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

FounderMr. Hugh Stephen Griffith

Chief Financial OfficerMr. Ian Webster

Head of Translational Medicine & StudiesProf. David Harrison

M.D.Dr. Jeffrey D. Bloss F.A.C.O.G.

Chief Operating OfficerMs. Theresa Bruce

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NuCana plc ADR

Upgrade your Finviz experience